[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:nras-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"NRAS Gene",17,16,[8,16,23,29,34,40,46,53,59,65,71,77,83,89,95,101,107],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06411821","Ulixertinib in People With Histiocytic Neoplasms",[12],"Phase 2","RECRUITING","2026-08-26T02:17:05.997056Z","2026-07-05T05:32:16.753306Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07318324","Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer",[20],"Phase 1","2026-08-26T02:17:46.653867Z","2026-07-05T05:32:16.676290Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07584226","A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors",[20],"2026-08-26T02:16:52.995882Z","2026-05-29T15:36:40.197011Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":21,"content_modified":33},"NCT06504459","Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML",[12],"2026-05-05T02:43:28.882922Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":38,"content_modified":39},"NCT06096974","Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS",[20],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:28.566526Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":44,"content_modified":45},"NCT06152809","CIML NK Cells With Venetoclax for AML",[20],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.162326Z",{"nct_id":47,"title":48,"phases":49,"status":13,"updated_at":51,"content_modified":52},"NCT05849662","A Phase I\u002FII Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia",[50],"Phase 1\u002FPhase 2","2026-08-26T02:15:39.267524Z","2026-05-05T02:43:28.528927Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT07032727","Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations",[12],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:28.209956Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT06326411","A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors",[20],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.481677Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT07252479","Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations",[20],"2026-08-26T02:16:01.910993Z","2026-06-16T05:54:07.937487Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT06026410","KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors",[20],"2026-08-26T02:18:43.501109Z","2026-05-05T02:43:29.472498Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT03190941","Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients",[50],"2026-08-26T02:18:06.247899Z","2026-05-05T02:43:28.129328Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":87,"content_modified":88},"NCT05786924","Phase 1\u002F2 Trial of S241656 in Selected RAS\u002FMAPK Mutation- Positive Malignancies",[50],"2026-08-26T02:16:54.044282Z","2026-05-05T02:35:31.640479Z",{"nct_id":90,"title":91,"phases":92,"status":13,"updated_at":93,"content_modified":94},"NCT05111561","Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced\u002FMetastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer",[20],"2026-08-26T02:17:47.813245Z","2026-07-24T01:27:14.906567Z",{"nct_id":96,"title":97,"phases":98,"status":13,"updated_at":99,"content_modified":100},"NCT00001350","Study of Autoimmune Lymphoproliferative Syndrome (ALPS)",[],"2026-08-26T02:19:21.761002Z","2026-07-05T18:42:10.720090Z",{"nct_id":102,"title":103,"phases":104,"status":13,"updated_at":105,"content_modified":106},"NCT04888936","Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies",[],"2026-08-26T02:17:59.904383Z","2026-05-13T02:55:06.274852Z",{"nct_id":108,"title":109,"phases":110,"status":111,"updated_at":112,"content_modified":113},"NCT05554328","Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:36:04.680662Z","2026-05-05T02:43:27.963217Z"]